Optical coherence tomography in Alzheimer's disease. A meta-analysis [PDF]
, 2015 BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder, which is likely to start as mild cognitive impairment (MCI) several years before the its full-blown clinical manifestation.
Barboni, Piero +9 more
core +8 more sources
New insights into the genetic etiology of Alzheimer’s disease and related dementias
Nature Genetics, 2022 Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes.
C. Bellenguez +402 more
semanticscholar +1 more source
Nature Reviews Disease Primers, 2021 Alzheimer disease (AD) is biologically defined by the presence of β-amyloid-containing plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic neurodegenerative disease that causes an amnestic cognitive impairment in its prototypical presentation and non-amnestic cognitive impairment in its less common variants.
David S. Knopman +7 more
openaire +2 more sources
Fast identification of biological pathways associated with a quantitative trait using group lasso with overlaps. [PDF]
, 2012 Where causal SNPs (single nucleotide polymorphisms) tend to accumulate within biological pathways, the incorporation of prior pathways information into a statistical model is expected to increase the power to detect true associations in a genetic ...
Alzheimer's Disease Neuroimaging Initiative +2 more
core +1 more source
Relation of neuropathology with cognitive decline among older persons without dementia
Frontiers in Aging Neuroscience, 2013 Objective: Although it is now widely accepted that dementia has a long preclinical phase during which neuropathology accumulates and cognition declines, little is known about the relation of neuropathology with the longitudinal rate of change in ...
Patricia eBoyle +4 more
doaj +1 more source
An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy [PDF]
, 2015 BackgroundImaging biomarkers for Alzheimer's disease include medial temporal lobe atrophy (MTLA) depicted on computed tomography (CT) or magnetic resonance imaging (MRI) and patterns of reduced metabolism on fluorodeoxyglucose positron emission ...
Cam Donaldson +13 more
core +1 more source
Risk Aversion is Associated with Decision Making among Community-Based Older Persons
Frontiers in Psychology, 2012 Background: Risk aversion is associated with many important decisions among younger and middle aged persons, but the association of risk aversion and decision making has not been well studied among older persons who face some of the most significant ...
Patricia eBoyle +3 more
doaj +1 more source
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023 INTRODUCTION Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at amyloid plaques.
Lawrence S. Honig +8 more
doaj +1 more source
The amyloid hypothesis of Alzheimer's disease at 25 years
EMBO Molecular Medicine, 2016 Despite continuing debate about the amyloid β‐protein (or Aβ hypothesis, new lines of evidence from laboratories and clinics worldwide support the concept that an imbalance between production and clearance of Aβ42 and related Aβ peptides is a very early,
D. Selkoe, J. Hardy
semanticscholar +1 more source
Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. [PDF]
, 2018 IntroductionWe characterize long-term disease dynamics from cognitively healthy to dementia using data from the Alzheimer's Disease Neuroimaging Initiative.MethodsWe apply a latent time joint mixed-effects model to 16 cognitive, functional, biomarker ...
Aisen, Paul S +5 more
core +1 more source